Biosimilars Market Forecast Highlighting Key Drivers And Expansion Potential

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Biosimilars Market Projected To Reach By 2030?

The biosimilars market has demonstrated significant expansion in recent years. It is anticipated to increase from $21.85 billion in 2025 to $25.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.9%. The growth observed in the historic period is largely attributable to the rising prevalence of chronic and autoimmune diseases, the significant expense associated with originator biologics, an increasing demand for cost-effective therapies, continuous advancements in biopharmaceutical research and development, and the developing healthcare infrastructure in emerging economies.

The biosimilars market is projected to experience substantial expansion in the coming years. By 2030, its value is anticipated to reach $48.52 billion, demonstrating a compound annual growth rate (CAGR) of 17.4%. This projected growth during the forecast period stems from factors such as the patent expiration of key biologics, a rise in the uptake of biosimilars for oncology and autoimmune treatments, favorable government incentives and policies, expanded manufacturing capacities in asia-pacific, and an increase in collaborations between biopharmaceutical firms and contract manufacturing organizations. Key trends observed for this period encompass the development of personalized biosimilars, more economical biologics production, improved regulatory alignment and adherence, the expansion of biosimilar markets in developing regions, and strategic alliances and partnerships.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Significant Factors Are Influencing The Biosimilars Market Expansion?

The increasing healthcare expenditures are projected to drive the expansion of the biosimilars market moving forward. Healthcare expenditures denote the overall spending on healthcare products and services within a particular population or medical system. The biosimilars market aids in diminishing healthcare expenditures by presenting more economical options compared to costly biologic drugs, thus reducing treatment costs for patients and healthcare systems. For instance, in March 2024, data from the Health Foundation, a UK-based independent charity and think tank, showed that in the most recently confirmed year for spending data, 2022/23, total health expenditures in England amounted to £182 billion ($196.78 billion). Although planned health spending is set to climb to £192 billion ($207.59 billion) by 2024/25, inflation will result in only a slight real-term increase of 0.6% compared to the 2023/24 fiscal year. Consequently, the rising healthcare expenditures are propelling the growth of the biosimilars market.

Which Segment Categories Are Included In The Biosimilars Market Segment Analysis?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

What Emerging Trends Are Seen In The Biosimilars Market?

Leading entities within the biosimilars sector prioritize the creation of groundbreaking products to secure a competitive advantage. FYLNETRA, a leukocyte growth factor, is prescribed to reduce the occurrence of infection, particularly febrile neutropenia, in individuals with non-myeloid malignancies who are undergoing myelosuppressive anti-cancer drug treatments that carry a clinically notable risk of febrile neutropenia. An illustrative case occurred in May 2023, when Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the US, commercially introduced FYLNETRA (pegfilgrastim-pbbk), which is a biosimilar drug mirroring Neulasta, provided in a pre-filled, single-dose syringe. The drug FYLNETRA addresses neutropenia (a condition characterized by low levels of neutrophils, a crucial type of white blood cell for combating infection), a common side effect for patients undergoing chemotherapy.

Who Are The Active Companies Shaping The Biosimilars Market?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Get The Full Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Where Is The Biosimilars Market Most Concentrated Geographically?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795